Mucin-1 tumor-associated glycoform (TA-MUC1)

Mucin-1 (MUC1) is a high-molecular-weight transmembrane glycoprotein normally expressed on the apical surface of epithelial cells, where it serves as a protective barrier and lubricant (Source: NIH, 1.2.2, 1.4.1). In malignant cells, MUC1 undergoes significant changes, including massive overexpression, loss of apical-basal polarity, and aberrant glycosylation, leading to the formation of the tumor-associated glycoform (TA-MUC1) (Source: NIH, 1.2.1, 1.2.2). This tumor glycoform is characterized by truncated O-glycans, such as the Tn, sialyl-Tn (STn), and Thomsen-Friedenreich (T) antigens, which expose the protein core and create novel neoepitopes (Source: MDPI, 1.3.5). TA-MUC1 plays a critical role in oncogenesis by promoting cell signaling pathways like MAPK and PI3K/Akt, enhancing tumor cell survival, and facilitating metastasis through interactions with selectins and galectins (Source: NIH, 1.1.4, 1.4.2). Therapeutically, the unique structural features of the MUC1 tumor glycoform make it an ideal target for precision oncology, as these epitopes are largely absent in healthy tissues (Source: NIH, 1.2.1, 1.3.3). Current drug development strategies include monoclonal antibodies like gatipotuzumab, antibody-drug conjugates (ADCs) such as DS-3939, and various cancer vaccines like tecemotide designed to elicit an immune response against the aberrant glycopeptide (Source: ESMO, 1.3.3; NIH, 1.3.2). Additionally, chimeric antigen receptor (CAR) T-cell therapies targeting specific glycoforms like Tn-MUC1 are being explored to provide potent and selective anti-tumor activity (Source: NIH, 1.2.3, 1.3.5). Despite its promise, challenges remain regarding the heterogeneity of MUC1 expression and potential safety concerns such as interstitial lung disease observed with certain MUC1-targeted agents (Source: ESMO, 1.3.3).

Other names

MUC1Tumor-associated Mucin-1CD227Epithelial membrane antigen (EMA)Polymorphic epithelial mucin (PEM)CA 15-3CA 27.29KL-6MAM6Episialin

Antibody-drug conjugate (ADC) delivering cytotoxic payloads, antibody-dependent cellular cytotoxicity (ADCC), T-cell activation via vaccines, inhibition of MUC1-C signaling, and CAR-T cell mediated cytotoxicity.